Market Overview:
The global traditional chemotherapy drugs for multiple myeloma market is expected to register a CAGR of 7.8% during the forecast period, 2018-2030. The market growth can be attributed to factors such as increasing incidence of multiple myeloma, rising demand for better treatment options, and technological advancements in the field of oncology. Based on type, the global traditional chemotherapy drugs for multiple myeloma market is segmented into melphalan, vincristine, cyclophosphamide, etoposide, doxorubicin liposome doxorubicin (Doxil), bendamustine and other types. Melphalan held a dominant share in the market in 2017 and is expected to maintain its dominance during the forecast period as well. This can be attributed to its high efficacy and safety profile coupled with low cost as compared to other drugs in this category.
Product Definition:
Traditional chemotherapy drugs for multiple myeloma are used to treat the disease by damaging or killing cancer cells.
Melphalan:
Melphalan, a cytotoxic chemical, is used in chemotherapy to treat multiple myeloma. It's primary action is to inhibit the synthesis of DNA and RNA. However, it also has some other effects such as causing liver damage and kidney failure. The drug was first synthesized by a research group at the University of Chicago in 1965; it was later on developed by Merck & Co., Inc.
Vincristine:
Vincristine is a chemotherapy drug and it's used in the treatment of multiple myeloma. Multiple Myeloma is also known as plasma cell cancer which develops from the plasma cells located in the bone marrow. Vincristine works by damaging the myeloma cells which then prompts them to divide rapidly before they have a chance to grow into an abnormal mass. The rapid division of myeloma cells leads to their destruction thus reducing their number and size.
Application Insights:
The hospital application segment dominated the global market for traditional chemotherapy drugs for multiple myeloma with a share of 60.0% in 2017. The dominance is attributed to the increasing prevalence of cancer and rising number of research initiatives by various companies including Pfizer, Novartis, and sanofi-aventis across the globe. For instance, in March 2018, sanofi-aventis announced about entering into a partnership with UPMC Hamot for development of new oncology therapies including melphalan chemo therapy as an alternative to bone metastasis surgery which will enable patients suffering from kidney cancer to receive treatment at one of its hospitals located in the U.S.
In addition, there are several other factors responsible for driving demand such as high cost associated with drug discovery & development and low penetration rate resulting in high unmet needs especially among low-income countries that are expected to drive growth over the forecast period (2017 - 2030).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high investment in research and development, availability of novel drug formulations, and supportive government initiatives. For instance, Keytruda (pembrolizumab) is a monoclonal antibody developed by Merck & Co., which received accelerated approval from the U.S FDA for treatment of relapsed or refractory multiple myeloma in October 2016. Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing healthcare expenditure levels coupled with rising patient awareness levels regarding available treatment options for MM.
In November 2015; Novartis AG announced that it was suspending its commercialization activities in China until further notice due to an outbreak of MDR/MDS cases associated with contaminated cyclophosphamide tablets imported from China (Novartis 2015).
Growth Factors:
- Increasing incidence of multiple myeloma
- Growing demand for novel and targeted therapies for multiple myeloma
- Rising awareness about multiple myeloma and its treatment options
- Availability of government funding for the development of new drugs for the treatment of multiple myeloma
- Technological advancements in chemotherapy drugs development
Scope Of The Report
Report Attributes
Report Details
Report Title
Traditional Chemotherapy Drugs for Multiple Myeloma Market Research Report
By Type
Melphalan, Vincristine, Cyclophosphamide, Etoposide, Doxorubicin, Liposome Doxorubicin, Bendamustine, Other
By Application
Hospital, Clinic, Drug Center, Other
By Companies
GlaxoSmithKline, Celon Laboratories, Natco Pharma, Emcure Pharmaceuticals, GLS Pharma, Talon Therapeutics, Shenzhen Main Luck Pharmaceuticals, Cipla, ACTIZA, Hospira, Baxter, Roxane, Sanofi, CSC Pharmaceuticals, LGM Pharma, Pfizer, Merck, Allergan, Teva, Mylan, Qilu Pharmaceutical, Sun Pharmaceuticals, Cadila Pharmaceuticals, Simcere Pharmaceutical, Get Well Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
185
Number of Tables & Figures
130
Customization Available
Yes, the report can be customized as per your need.
Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Report Segments:
The global Traditional Chemotherapy Drugs for Multiple Myeloma market is segmented on the basis of:
Types
Melphalan, Vincristine, Cyclophosphamide, Etoposide, Doxorubicin, Liposome Doxorubicin, Bendamustine, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Celon Laboratories
- Natco Pharma
- Emcure Pharmaceuticals
- GLS Pharma
- Talon Therapeutics
- Shenzhen Main Luck Pharmaceuticals
- Cipla
- ACTIZA
- Hospira
- Baxter
- Roxane
- Sanofi
- CSC Pharmaceuticals
- LGM Pharma
- Pfizer
- Merck
- Allergan
- Teva
- Mylan
- Qilu Pharmaceutical
- Sun Pharmaceuticals
- Cadila Pharmaceuticals
- Simcere Pharmaceutical
- Get Well Pharmaceutical
Highlights of The Traditional Chemotherapy Drugs for Multiple Myeloma Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Melphalan
- Vincristine
- Cyclophosphamide
- Etoposide
- Doxorubicin
- Liposome Doxorubicin
- Bendamustine
- Other
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Traditional Chemotherapy Drugs for Multiple Myeloma Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Traditional chemotherapy drugs for multiple myeloma are alkylating agents such as nitrogen mustards, anthracyclines, and platinum-based drugs. These medications work by damaging the DNA in the cancer cells.
Some of the major players in the traditional chemotherapy drugs for multiple myeloma market are GlaxoSmithKline, Celon Laboratories, Natco Pharma, Emcure Pharmaceuticals, GLS Pharma, Talon Therapeutics, Shenzhen Main Luck Pharmaceuticals, Cipla, ACTIZA, Hospira, Baxter, Roxane, Sanofi, CSC Pharmaceuticals, LGM Pharma, Pfizer, Merck, Allergan, Teva, Mylan, Qilu Pharmaceutical, Sun Pharmaceuticals, Cadila Pharmaceuticals, Simcere Pharmaceutical, Get Well Pharmaceutical.
The traditional chemotherapy drugs for multiple myeloma market is expected to register a CAGR of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Traditional Chemotherapy Drugs for Multiple Myeloma Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Traditional Chemotherapy Drugs for Multiple Myeloma Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Traditional Chemotherapy Drugs for Multiple Myeloma Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Traditional Chemotherapy Drugs for Multiple Myeloma Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Size & Forecast, 2018-2028
4.5.1 Traditional Chemotherapy Drugs for Multiple Myeloma Market Size and Y-o-Y Growth
4.5.2 Traditional Chemotherapy Drugs for Multiple Myeloma Market Absolute $ Opportunity
Chapter 5 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
5.2.1 Melphalan
5.2.2 Vincristine
5.2.3 Cyclophosphamide
5.2.4 Etoposide
5.2.5 Doxorubicin
5.2.6 Liposome Doxorubicin
5.2.7 Bendamustine
5.2.8 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Drug Center
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Traditional Chemotherapy Drugs for Multiple Myeloma Analysis and Forecast
9.1 Introduction
9.2 North America Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
9.6.1 Melphalan
9.6.2 Vincristine
9.6.3 Cyclophosphamide
9.6.4 Etoposide
9.6.5 Doxorubicin
9.6.6 Liposome Doxorubicin
9.6.7 Bendamustine
9.6.8 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Drug Center
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Analysis and Forecast
10.1 Introduction
10.2 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
10.6.1 Melphalan
10.6.2 Vincristine
10.6.3 Cyclophosphamide
10.6.4 Etoposide
10.6.5 Doxorubicin
10.6.6 Liposome Doxorubicin
10.6.7 Bendamustine
10.6.8 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Drug Center
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
11.6.1 Melphalan
11.6.2 Vincristine
11.6.3 Cyclophosphamide
11.6.4 Etoposide
11.6.5 Doxorubicin
11.6.6 Liposome Doxorubicin
11.6.7 Bendamustine
11.6.8 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Drug Center
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Traditional Chemotherapy Drugs for Multiple Myeloma Analysis and Forecast
12.1 Introduction
12.2 Latin America Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
12.6.1 Melphalan
12.6.2 Vincristine
12.6.3 Cyclophosphamide
12.6.4 Etoposide
12.6.5 Doxorubicin
12.6.6 Liposome Doxorubicin
12.6.7 Bendamustine
12.6.8 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Drug Center
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Traditional Chemotherapy Drugs for Multiple Myeloma Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
13.6.1 Melphalan
13.6.2 Vincristine
13.6.3 Cyclophosphamide
13.6.4 Etoposide
13.6.5 Doxorubicin
13.6.6 Liposome Doxorubicin
13.6.7 Bendamustine
13.6.8 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Traditional Chemotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Drug Center
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Traditional Chemotherapy Drugs for Multiple Myeloma Market: Competitive Dashboard
14.2 Global Traditional Chemotherapy Drugs for Multiple Myeloma Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Celon Laboratories
14.3.3 Natco Pharma
14.3.4 Emcure Pharmaceuticals
14.3.5 GLS Pharma
14.3.6 Talon Therapeutics
14.3.7 Shenzhen Main Luck Pharmaceuticals
14.3.8 Cipla
14.3.9 ACTIZA
14.3.10 Hospira
14.3.11 Baxter
14.3.12 Roxane
14.3.13 Sanofi
14.3.14 CSC Pharmaceuticals
14.3.15 LGM Pharma
14.3.16 Pfizer
14.3.17 Merck
14.3.18 Allergan
14.3.19 Teva
14.3.20 Mylan
14.3.21 Qilu Pharmaceutical
14.3.22 Sun Pharmaceuticals
14.3.23 Cadila Pharmaceuticals
14.3.24 Simcere Pharmaceutical
14.3.25 Get Well Pharmaceutical
